Cargando…
HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
A comprehensive characterization of chronic HBV (CHB) patients is required to guide therapeutic decisions. The cumulative impact of classical and novel biomarkers on the clinical categorization of these patients has not been rigorously assessed. We determined plasma HBV-RNA and HBsAg levels, HBV in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949614/ https://www.ncbi.nlm.nih.gov/pubmed/35336990 http://dx.doi.org/10.3390/v14030584 |
_version_ | 1784674939782037504 |
---|---|
author | Gozlan, Yael Aaron, Daniella Davidov, Yana Likhter, Maria Ben Yakov, Gil Cohen-Ezra, Oranit Picard, Orit Erster, Oran Mendelson, Ella Ben-Ari, Ziv Abu Baker, Fadi Mor, Orna |
author_facet | Gozlan, Yael Aaron, Daniella Davidov, Yana Likhter, Maria Ben Yakov, Gil Cohen-Ezra, Oranit Picard, Orit Erster, Oran Mendelson, Ella Ben-Ari, Ziv Abu Baker, Fadi Mor, Orna |
author_sort | Gozlan, Yael |
collection | PubMed |
description | A comprehensive characterization of chronic HBV (CHB) patients is required to guide therapeutic decisions. The cumulative impact of classical and novel biomarkers on the clinical categorization of these patients has not been rigorously assessed. We determined plasma HBV-RNA and HBsAg levels, HBV in peripheral lymphocytes (PBMCs) and HBV mutation profiles in CHB patients. Patient demographics (n = 139) and classical HBV biomarkers were determined during a clinical routine. HBV-RNA in plasma and HBV-DNA in PBMCs were determined by RT-PCR. HBsAg levels were determined using Architect. In samples with HBV-DNA viral load >1000 IU/mL, genotype mutations in precore (PC), basal core promoter (BCP), HBsAg and Pol regions were determined by sequencing. Most patients (n = 126) were HBeAg-negative (HBeAgNeg) with significantly lower levels of HBV-RNA, HBV-DNA and HBsAg compared to HBeAg-positive (HBeAgPos) patients (p < 0.05). HBV genotype D prevailed (61/68), and >95% had BCP/PC mutations. Escape mutations were identified in 22.6% (13/63). HBeAgNeg patients with low levels of HBsAg (log IU ≤ 3) were older and were characterized by undetectable plasma HBV-DNA and undetectable HBV-RNA but not undetectable HBV-DNA in PBMCs compared to those with high HBsAg levels. In >50% of the studied HBeAgNeg patients (66/126), the quantitation of HBsAg and HBV-RNA may impact clinical decisions. In conclusion, the combined assessment of classical and novel serum biomarkers, especially in HBeAgNeg patients, which is the largest group of CHB patients in many regions, may assist in clinical decisions. Prospective studies are required to determine the real-time additive clinical advantage of these biomarkers. |
format | Online Article Text |
id | pubmed-8949614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89496142022-03-26 HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B Gozlan, Yael Aaron, Daniella Davidov, Yana Likhter, Maria Ben Yakov, Gil Cohen-Ezra, Oranit Picard, Orit Erster, Oran Mendelson, Ella Ben-Ari, Ziv Abu Baker, Fadi Mor, Orna Viruses Article A comprehensive characterization of chronic HBV (CHB) patients is required to guide therapeutic decisions. The cumulative impact of classical and novel biomarkers on the clinical categorization of these patients has not been rigorously assessed. We determined plasma HBV-RNA and HBsAg levels, HBV in peripheral lymphocytes (PBMCs) and HBV mutation profiles in CHB patients. Patient demographics (n = 139) and classical HBV biomarkers were determined during a clinical routine. HBV-RNA in plasma and HBV-DNA in PBMCs were determined by RT-PCR. HBsAg levels were determined using Architect. In samples with HBV-DNA viral load >1000 IU/mL, genotype mutations in precore (PC), basal core promoter (BCP), HBsAg and Pol regions were determined by sequencing. Most patients (n = 126) were HBeAg-negative (HBeAgNeg) with significantly lower levels of HBV-RNA, HBV-DNA and HBsAg compared to HBeAg-positive (HBeAgPos) patients (p < 0.05). HBV genotype D prevailed (61/68), and >95% had BCP/PC mutations. Escape mutations were identified in 22.6% (13/63). HBeAgNeg patients with low levels of HBsAg (log IU ≤ 3) were older and were characterized by undetectable plasma HBV-DNA and undetectable HBV-RNA but not undetectable HBV-DNA in PBMCs compared to those with high HBsAg levels. In >50% of the studied HBeAgNeg patients (66/126), the quantitation of HBsAg and HBV-RNA may impact clinical decisions. In conclusion, the combined assessment of classical and novel serum biomarkers, especially in HBeAgNeg patients, which is the largest group of CHB patients in many regions, may assist in clinical decisions. Prospective studies are required to determine the real-time additive clinical advantage of these biomarkers. MDPI 2022-03-11 /pmc/articles/PMC8949614/ /pubmed/35336990 http://dx.doi.org/10.3390/v14030584 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gozlan, Yael Aaron, Daniella Davidov, Yana Likhter, Maria Ben Yakov, Gil Cohen-Ezra, Oranit Picard, Orit Erster, Oran Mendelson, Ella Ben-Ari, Ziv Abu Baker, Fadi Mor, Orna HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B |
title | HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B |
title_full | HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B |
title_fullStr | HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B |
title_full_unstemmed | HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B |
title_short | HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B |
title_sort | hbv-rna, quantitative hbsag, levels of hbv in peripheral lymphocytes and hbv mutation profiles in chronic hepatitis b |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949614/ https://www.ncbi.nlm.nih.gov/pubmed/35336990 http://dx.doi.org/10.3390/v14030584 |
work_keys_str_mv | AT gozlanyael hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT aarondaniella hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT davidovyana hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT likhtermaria hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT benyakovgil hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT cohenezraoranit hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT picardorit hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT ersteroran hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT mendelsonella hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT benariziv hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT abubakerfadi hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb AT mororna hbvrnaquantitativehbsaglevelsofhbvinperipherallymphocytesandhbvmutationprofilesinchronichepatitisb |